A study of HP568 for advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new oral drug called HP568 for people with a specific type of advanced breast cancer (ER+/HER2-). It may help those whose cancer has progressed after prior hormone therapy or chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- You have advanced breast cancer that is ER-positive and HER2-negative (confirmed by lab tests).
- You have had at least one prior hormone therapy for advanced disease that lasted 6 months or more.
- You have had no more than two prior chemotherapies for advanced disease (in some stages).
- Your cancer has gotten worse during or after your last treatment before this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This study looks at how well CDK4/6 inhibitors (a type of targeted therapy) work in real-world patients with HR+/HER2- advanced breast cancer. By collecting medical data from people treated at this hospital, doctors hope to learn more about the effectiveness and safety of these drugs in everyday practice.
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.